Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that v::ROS1 status confers therapeutic sensitivity to Repotrectinib in patients with Non-Small Cell Lung Cancer.
This statement is based on a regulatory approval from the Health Canada:
AUGTYRO (repotrectinib capsules) is indicated for treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).